



Contents lists available at ScienceDirect

Prostaglandins, Leukotrienes and Essential Fatty Acids

journal homepage: www.elsevier.com/locate/plefa

Corrigendum

Corrigendum to “Hemodialysis and Biotransformation of Erythrocyte Epoxy Fatty Acids in Peripheral Tissue”

Tong Liu^a, Inci Dogan^d, Michael Rothe^d, Julius V. Kunz^b, Felix Knaufl^b, Maik Gollasch^e, Friedrich C. Luft^a, Benjamin Gollasch^{a,b,c,*}^a Experimental and Clinical Research Center (ECRC), a joint institution of the Charité Medical Faculty and Max Delbrück Center (MDC) for Molecular Medicine, 13125 Berlin^b Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin^c HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125 Berlin^d LIPIDOMIX GmbH, Robert-Rössle-Str. 10, 13125 Berlin^e Department of Internal Medicine and Geriatrics, University Medicine Greifswald, 17475 Greifswald, Germany

[Prostaglandins, Leukotrienes and Essential Fatty Acids, Volume 181, June 2022, 102453]

DOI of original article: DOI: 10.1016/j.plefa.2022.102453

The authors regret that an error occurred in the published version when editing the proofs, resulting in incorrect and redundant conclusions being listed in the "Highlights Section".

After careful review, the highlight sentences should read as follows:

- 1) Hemodialysis affects the arteriovenous differences of numerous erythro-LOX metabolites in the peripheral circulation.
- 2) Erythro-epoxy fatty acids could contribute to cardiovascular risk.

Table 1

Characteristics of hemodialysis (HD) patients (n=12).

	HD patients
Age (years)	72±12
Sex	
Male (n)	9
Female (n)	3
Body mass index (kg/m ²)	27±3.3
Race (n)	Caucasian = 12
Cause of end-stage renal disease	
Focal segmental glomerulosclerosis	6
IgA nephropathy (n)	1
Renal amyloidosis	1
Hypertension (n)	1
Drug induced (n)	1
ADPKD (n)	1
Cystic kidneys	1
Complications	
Cardiovascular (n)	12

Notes: Data are presented as mean ± SD or frequencies.

DOI of original article: <https://doi.org/10.1016/j.plefa.2022.102453>.

* Corresponding author. Experimental and Clinical Research Center (ECRC), a joint institution of the Charité Medical Faculty and Max Delbrück Center (MDC) for Molecular Medicine, Berlin 13125, Germany

E-mail address: benjamin.gollasch@charite.de (B. Gollasch).<https://doi.org/10.1016/j.plefa.2022.102521>Available online 7 December 2022
0952-3278/© 2022 Published by Elsevier Ltd.

Table 2

Effects of hemodialysis on hydroxy- and epoxy-metabolites in the CKD patients before (pre-HD) and at cessation (post-HD) of hemodialysis (n=12 each).

Amount ng/g	pre-HD Arterial	pre-HD Venous	p value, t test (# paired Wilcoxon test)	pre-HD Δ_A v	post-HD Arterial	post-HD Venous	p value, t test (# paired Wilcoxon test)	post-HD Δ_A v
Panel A: Total metabolite levels.								
LOX metabolites								
5-HETE	192.57 ±25.35	198.56 ±32.71	0.511	-5.99 ±30.53	207.64 ±48.27	173.93 ±31.81	0.003	33.71 ±30.31
8-HETE	56.64 ±11.68	56.70 ±9.36	0.991	-0.05 ±15.81	63.03 ±12.45	56.56 ±9.36	0.038	6.47 ±9.50
9-HETE	154.21 ±19.56	159.42 ±18.96	0.388 #	-5.21 ±25.47	171.28 ±40.78	136.62 ±24.32	0.008	34.65 ±37.45
11-HETE	178.41 ±41.70	179.03 ±46.16	0.948	-0.61 ±31.52	184.55 ±66.18	171.73 ±57.79	0.34	12.83 ±44.57
12-HETE	413.36 ±143.96	469.21 ±325.75	0.638 #	-55.85 ±297.34	610.90 ±502.51	352.44 ±141.85	0.071 #	258.47 ±497.92
15-HETE	328.57 ±59.64	331.87 ±65.68	0.844	-3.30 ±56.56	337.74 ±92.64	306.33 ±85.33	0.097	31.41 ±60.08
4-HDHA	115.75 ±40.87	113.58 ±38.50	0.754	2.17 ±23.38	113.09 ±53.8986	104.4464 ±43.3149	0.263	8.6433 ±25.3880
7-HDHA	24.96 ±8.22	25.15 ±4.15	0.388 #	-0.19 ±7.02	28.55 ±8.34	22.08 ±5.51	0.013	6.47 ±7.53
8-HDHA	29.24 ±9.97	27.28 ±9.25	0.373	1.95 ±7.29	33.09 ±12.20	26.17 ±10.39	0.003	6.92 ±6.43
10-HDHA	20.09 ±6.25	20.06 ±5.02	0.988	0.02 ±4.88	21.58 ±6.45	18.34 ±6.65	0.029	3.24 ±4.48
11-HDHA	37.79 ±24.86	38.53 ±21.33	0.806	-0.73 ±10.17	34.92 ±28.61	35.36 ±22.06	0.935	-0.44 ±18.05
13-HDHA	45.76 ±17.61	47.91 ±19.64	0.523	-2.14 ±11.24	46.84 ±22.55	43.02 ±21.02	0.301	3.82 ±12.21
14-HDHA	45.92 ±18.73	48.43 ±15.56	0.53 #	-2.51 ±16.62	55.82 ±33.11	37.95 ±10.82	0.034 #	17.87 ±33.36
16-HDHA	58.53 ±27.04	59.80 ±25.79	0.804	-1.28 ±17.38	56.87 ±28.82	54.85 ±28.15	0.663	2.02 ±15.62
17-HDHA	71.77 ±30.09	70.33 ±27.14	0.725	1.44 ±13.80	70.20 ±31.59	64.84 ±30.06	0.28	5.37 ±16.39
20-HDHA	143.35 ±63.29	141.64 ±55.32	0.868	1.71 ±34.73	142.83 ±66.65	130.52 ±60.98	0.257	12.31 ±35.68
5-HEPE	14.85 ±6.92	13.80 ±5.68	0.519	1.05 ±5.44	15.04 ±5.91	12.94 ±5.66	0.167	2.11 ±4.94
8-HEPE	2.09 ±0.85	2.20 ±0.60	0.631	-0.11 ±0.77	2.56 ±0.89	1.85 ±0.72	0.042	0.71 ±1.07
9-HEPE	5.35 ±2.36	5.14 ±1.65	0.74	0.22 ±2.19	6.44 ±2.45	4.45 ±1.91	0.02	1.99 ±2.54
11-HEPE	21.94 ±16.25	23.29 ±13.88	0.655	-1.35 ±10.19	21.15 ±16.16	20.49 ±13.96	0.854	0.66 ±12.11
12-HEPE	38.22 ±21.81	42.08 ±19.71	0.754 #	-3.86 ±19.33	49.19 ±44.12	24.26 ±9.95	0.023 #	24.93 ±44.72
15-HEPE	6.88 ±3.40	7.37 ±2.93	0.485	-0.49 ±2.35	7.62 ±2.84	6.16 ±3.07	0.056	1.46 ±2.37
18-HEPE	20.23 ±7.43	19.27 ±6.61	0.587	0.96 ±5.95	20.58 ±7.48	17.87 ±8.10	0.108	2.71 ±5.38
CYP $\omega/(\omega-1)$ metabolites								
16-HETE	11.35 ±4.51	14.09 ±5.15	0.015 #	-2.74 ±3.03	11.13 ±5.28	10.90 ±4.83	0.877	0.23 ±5.03
17-HETE	0.23 ±0.08	0.26 ±0.07	0.16	-0.03 ±0.06	0.23 ±0.07	0.21 ±0.06	0.361	0.02 ±0.07
18-HETE	0.64 ±0.26	0.67 ±0.20	0.587	-0.03 ±0.17	0.68 ±0.26	0.63 ±0.23	0.546	0.04 ±0.24
19-HETE	0.32 ±0.11	0.35 ±0.14	0.136 #	-0.03 ±0.07	0.35 ±0.17	0.28 ±0.10	0.182 #	0.07 ±0.17
20-HETE	0.589 ±0.138	0.63 ±0.24	0.695 #	-0.05 ±0.15	0.64 ±0.15	0.53 ±0.18	0.03	0.10 ±0.14
9-HODE	95.46 ±20.97	105.22 ±15.95	0.027	-9.76 ±13.27	112.39 ±38.96	94.99 ±25.11	0.239 #	17.40 ±43.98
13-HODE	108.45 ±26.10	117.85 ±16.26	0.142	-9.40 ±20.58	131.67 ±51.38	103.24 ±31.34	0.06 #	28.43 ±58.70
22-HDHA	0.26 ±0.14	0.33 ±0.23	0.182 #	-0.06 ±0.19	0.25 ±0.13	0.23 ±0.14	0.616	0.02 ±0.15
20-HEPE	0.26 ±0.14	0.10 ±0.17	1 #	0.01 ±0.04	0.05 ±0.07	0.05 ±0.10	0.893 #	0.00 ±0.08
CYP epoxy-metabolites								
5,6-EET	62.22 ±68.30	69.46 ±65.90	0.308 #	-7.24 ±21.79	91.36 ±99.99	56.52 ±63.89	0.347 #	34.84 ±83.99
8,9-EET	62.07 ±16.10	65.90 ±13.95	0.524	-3.83 ±20.17	76.50 ±22.04	63.37 ±14.10	0.067	13.13 ±22.35
11,12-EET	69.88 ±14.41	75.19 ±19.91	0.513	-5.30 ±27.17	84.18 ±25.51	69.94 ±15.93	0.136 #	14.24 ±28.98
14,15-EET	92.07 ±25.43	103.57 ±31.77	0.306	-11.49 ±37.08	109.32 ±40.86	94.90 ±24.38	0.182 #	14.41 ±42.81
5,6-DHET	2.57 ±0.60	2.84 ±0.76	0.084 #	-0.27 ±0.47	2.68 ±0.86	2.24 ±0.50	0.085	0.43 ±0.80
8,9-DHET	3.44 ±1.64	3.66 ±1.67	0.209 #	-0.21 ±0.79	3.48 ±1.62	3.03 ±1.50	0.099 #	0.45 ±1.15
11,12-DHET	1.66 ±0.64	1.66 ±0.63	0.875 #	0.00 ±0.44	1.76 ±0.48	1.49 ±0.47	0.004	0.27 ±0.26

(continued on next page)

Table 2 (continued)

Amount ng/g	pre-HD Arterial	pre-HD Venous	p value, t test (# paired Wilcoxon test)	pre-HD Δ_A v	post-HD Arterial	post-HD Venous	p value, t test (# paired Wilcoxon test)	post-HD Δ_A v
14,15-DHET	2.29 ±0.35	2.29 ±0.38	0.956	-0.01 ±0.48	2.35 ±0.35	2.14 ±0.27	0.177	0.21 ±0.49
9,10-EpOME	37.19 ±15.89	40.17 ±11.39	0.386	-2.99 ±11.46	54.47 ±28.71	40.01 ±17.56	0.128	14.46 ±30.45
12,13-EpOME	39.69 ±12.91	43.09 ±8.73	0.385	-3.40 ±13.02	55.17 ±21.02	43.09 ±13.08	0.071 #	12.08 ±24.98
9,10-DiHOME	1.98 ±1.28	2.13 ±1.43	0.638 #	-0.15 ±0.74	2.72 ±2.06	2.36 ±1.93	0.638 #	0.35 ±2.03
12,13-DiHOME	3.49 ±1.35	3.36 ±1.56	0.583 #	0.13 ±1.04	4.50 ±2.83	4.57 ±2.95	0.347 #	-0.07 ±2.67
7,8-EDP	39.28 ±19.86	40.07 ±18.50	0.695 #	-0.79 ±21.07	44.29 ±16.39	39.12 ±13.12	0.241	5.16 ±14.42
10,11-EDP	18.95 ±8.56	20.22 ±7.14	0.613	-1.27 ±8.45	25.07 ±9.45	18.32 ±5.64	0.03	6.75 ±9.39
13,14-EDP	17.88 ±9.99	19.76 ±10.12	0.569	-1.88 ±11.10	18.31 ±7.98	14.44 ±4.46	0.144	3.88 ±8.54
16,17-EDP	32.72 ±16.513	36.67 ±15.08	0.474	-3.96 ±18.48	27.36 ±14.54	21.28 ±9.22	0.182 #	6.08 ±14.78
19,20-EDP	23.01 ±10.21	25.17 ±10.13	0.48 #	-2.16 ±12.00	32.01 ±11.74	22.38 ±6.48	0.019 #	9.63 ±12.86
7,8-DiHDPA	1.15 ±0.50	1.29 ±0.47	0.262	-0.14 ±0.40	1.32 ±0.71	1.22 ±0.48	0.596	0.10 ±0.62
10,11-DiHDPA	0.76 ±0.17	0.74 ±0.14	0.713	0.02 ±0.17	0.75 ±0.19	0.70 ±0.17	0.449	0.05 ±0.21
13,14-DiHDPA	0.85 ±0.33	0.77 ±0.21	0.464	0.08 ±0.38	0.87 ±0.39	0.89 ±0.38	0.859	-0.02 ±0.31
16,17-DiHDPA	0.48 ±0.16	0.49 ±0.12	0.831	-0.01 ±0.15	0.48 ±0.19	0.479 ±0.11	0.898	0.01 ±0.16
19,20-DiHDPA	1.19 ±0.43	1.09 ±0.28	0.402	0.10 ±0.39	1.28 ±0.35	1.05 ±0.25	0.108	0.23 ±0.45
5,6-EEQ	ns	ns	ns	ns	ns	ns	ns	ns
8,9-EEQ	3.10 ±2.48	2.69 ±1.17	0.58 #	0.40 ±2.45	4.22 ±2.60	2.76 ±1.40	0.028 #	1.46 ±2.12
11,12-EEQ	3.64 ±2.59	3.68 ±2.02	0.875 #	-0.04 ±3.04	4.89 ±1.72	3.58 ±1.29	0.029	1.30 ±1.80
14,15-EEQ	2.83 ±1.68	2.75 ±1.41	0.814 #	0.08 ±2.03	3.78 ±1.71	2.54 ±0.95	0.032	1.25 ±1.76
17,18-EEQ	4.74 ±4.03	4.09 ±2.08	0.937 #	0.65 ±3.02	7.42 ±6.13	4.67 ±3.85	0.071 #	2.75 ±5.54
5,6-DiHETE	2.61 ±0.98	1.71 ±0.46	0.011	0.90 ±1.03	2.21 ±0.73	2.09 ±0.49	0.875 #	0.12 ±0.83
8,9-DiHETE	0.22 ±0.17	0.17 ±0.06	0.272 #	0.05 ±0.14	0.21 ±0.09	0.19 ±0.05	0.695 #	0.02 ±0.10
11,12-DiHETE	3.80 ±2.55	3.56 ±1.68	0.777	0.24 ±2.90	5.30 ±2.66	4.70 ±3.49	0.388 #	0.60 ±4.32
14,15-DiHETE	0.13 ±0.10	0.11 ±0.04	0.937 #	0.020 ±0.10	0.05 ±0.07	0.05 ±0.10	0.041 #	0.04 ±0.06
17,18-DiHETE	0.44 ±0.17	0.39 ±0.11	0.219	0.05 ±0.14	0.43 ±0.16	0.45 ±0.22	1 #	-0.02 ±0.22
Panel B: Free metabolite levels.								
LOX metabolites								
5-HETE	2.50 ±1.67	2.51 ±2.93	0.638 #	-0.01 ±3.70	2.42 ±1.42	1.47 ±1.60	0.071 #	0.95 ±1.84
8-HETE	2.38 ±0.61	1.77 ±0.46	0.006	0.61 ±0.62	2.38 ±0.85	1.39 ±0.56	0.003	0.99 ±0.88
9-HETE	2.49 ±1.30	1.75 ±0.81	0.011	0.74 ±0.84	1.99 ±0.87	1.28 ±0.60	0.023	0.71 ±0.88
11-HETE	3.10 ±1.21	2.29 ±1.06	0.012 #	0.81 ±0.91	2.76 ±1.19	1.76 ±0.65	0.016	1.00 ±1.17
12-HETE	544.04 ±231.17	425.17 ±210.46	0.077	118.86 ±211.26	555.84 ±336.12	336.43 ±213.05	0.015	219.41 ±252.60
15-HETE	6.88 ±1.86	5.21 ±2.07	0.003	1.66 ±1.55	7.45 ±2.70	4.50 ±1.79	0.001	2.95 ±2.21
4-HDHA	0.23 ±0.11	0.20 ±0.09	0.169	0.03 ±0.07	0.21 ±0.09	0.13 ±0.07	0.001	0.08 ±0.06
7-HDHA	0.38 ±0.15	0.34 ±0.28	0.289 #	0.04 ±0.25	0.28 ±0.18	0.16 ±0.05	0.01 #	0.12 ±0.16
8-HDHA	4.17 ±3.73	3.59 ±4.05	0.433 #	0.59 ±1.87	3.74 ±3.54	2.02 ±1.93	0.035	1.72 ±2.37
10-HDHA	1.41 ±0.86	1.13 ±0.78	0.06 #	0.28 ±0.44	1.11 ±0.65	0.69 ±0.40	0.017	0.42 ±0.50
11-HDHA	5.39 ±3.80	4.41 ±3.20	0.099 #	0.98 ±1.80	3.57 ±2.41	2.18 ±1.47	0.031	1.38 ±1.87
13-HDHA	0.82 ±0.67	0.67 ±0.73	0.05 #	0.16 ±0.25	0.52 ±0.33	0.32 ±0.16	0.003 #	0.20 ±0.24
14-HDHA	30.72 ±21.13	25.10 ±18.55	0.117 #	5.62 ±11.16	23.18 ±17.75	14.14 ±9.38	0.043	9.04 ±13.07
16-HDHA	2.21 ±2.64	1.77 ±3.69	0.06 #	0.44 ±4.67	3.68 ±5.34	1.47 ±2.16	0.002 #	2.21 ±3.28
17-HDHA	1.84 ±1.02	1.40 ±0.82	0.028 #	0.44 ±0.59	1.46 ±0.70	0.86 ±0.40	0.001	0.60 ±0.47
20-HDHA	2.27 ±1.06	1.84 ±1.06	0.039	0.44 ±0.64	2.39 ±1.38	1.35 ±0.60	0.003 #	1.03 ±0.99
5-HEPE	0.52 ±0.29	0.50 ±0.61	0.347 #	0.02 ±0.69	0.51 ±0.48	0.23 ±0.17	0.041 #	0.28 ±0.48
8-HEPE	0.11 ±0.07	0.07 ±0.04	0.002 #	0.03 ±0.04	0.09 ±0.07	0.05 ±0.02	0.003 #	0.04 ±0.06
9-HEPE	0.32 ±0.27	0.21 ±0.13	0.006 #	0.11 ±0.17	0.25 ±0.22	0.13 ±0.04	0.006 #	0.12 ±0.21
11-HEPE	0.70 ±0.55	0.49 ±0.43	0.008 #	0.21 ±0.20	0.56 ±0.36	0.34 ±0.21	0.003 #	0.21 ±0.19
12-HEPE	43.51 ±25.87	35.57 ±23.18	0.102	7.94 ±15.42	31.16 ±21.78	18.21 ±11.77	0.034	12.95 ±17.70
15-HEPE	0.42 ±0.24	0.32 ±0.17	0.023 #	0.09 ±0.14	0.35 ±0.21	0.23 ±0.08	0.019 #	0.12 ±0.18
18-HEPE	0.60 ±0.28	0.41 ±0.14	0.013	0.19 ±0.22	0.57 ±0.33	0.33 ±0.12	0.003 #	0.24 ±0.28
CYP ω/(ω-1) metabolites								
16-HETE	0.09 ±0.03	0.08 ±0.02	0.084	0.01 ±0.02	0.10 ±0.03	0.08 ±0.01	0.272 #	0.01 ±0.03
17-HETE	ns	ns	ns #	ns	ns	ns #	ns	ns
18-HETE	0.04 ±0.01	0.04 ±0.01	0.798	0.00 ±0.01	0.045 ±0.02	0.04 ±0.02	0.35	0.01 ±0.03
19-HETE	0.01 ±0.01	0.00 ±0.01	1 #	0	0.01 ±0.02	0.01 ±0.02	1 #	0.00 ±0.01
20-HETE	0.07 ±0.07	0.13 ±0.08	0.013 #	-0.06 ±0.06	0.06 ±0.06	0.10 ±0.09	0.131 #	-0.04 ±0.07
9-HODE	24.96 ±16.21	45.28 ±99.25	0.209 #	-20.31 ±85.34	14.67 ±8.45	12.19 ±8.95	0.084 #	2.48 ±7.13
13-HODE	19.85 ±10.47	37.06 ±77.53	0.272 #	-17.21 ±71.57	12.38 ±7.03	9.17 ±6.28	0.041 #	3.20 ±5.05
22-HDHA	0.08 ±0.07	0.07 ±0.04	0.583 #	0.01 ±0.08	0.05 ±0.02	0.04 ±0.02	0.534 #	0.00 ±0.02
20-HEPE	0.03 ±0.04	0.03 ±0.05	0.866 #	0.00 ±0.06	0.01 ±0.03	0.03 ±0.04	0.138 #	-0.02 ±0.03

(continued on next page)

Table 2 (continued)

Amount ng/g	pre-HD Arterial	pre-HD Venous	p value, t test (# paired Wilcoxon test)	pre-HD Δ_{A-V}	post-HD Arterial	post-HD Venous	p value, t test (# paired Wilcoxon test)	post-HD Δ_{A-V}
CYP epoxy-metabolites								
5,6-EET	0.67 ±0.33	0.56 ±0.33	0.388 #	0.11 ±0.44	1.01 ±0.49	0.80 ±0.33	0.239 #	0.21 ±0.58
8,9-EET	1.37 ±0.77	1.43 ±1.02	0.846	-0.05 ±0.89	1.48 ±0.88	1.41 ±0.68	0.816	0.07 ±0.95
11,12-EET	0.80 ±0.31	0.59 ±0.26	0.099 #	0.22 ±0.41	1.19 ±0.60	0.94 ±0.38	0.288	0.25 ±0.78
14,15-EET	0.86 ±0.33	0.67 ±0.33	0.158 #	0.19 ±0.43	1.41 ±0.62	1.02 ±0.32	0.09	0.39 ±0.73
5,6-DHET	0.03 ±0.02	0.03 ±0.01	0.607	0.00 ±0.02	0.03 ±0.01	0.03 ±0.02	0.06 #	0.01 ±0.02
8,9-DHET	0.09 ±0.02	0.09 ±0.03	0.653	0.00 ±0.03	0.08 ±0.02	0.08 ±0.02	0.347 #	0.00 ±0.02
11,12-DHET	0.07 ±0.04	0.07 ±0.04	0.388 #	0.00 ±0.01	0.07 ±0.05	0.06 ±0.03	0.158 #	0.01 ±0.03
14,15-DHET	0.09 ±0.03	0.09 ±0.04	0.209 #	-0.01 ±0.02	0.09 ±0.04	0.08 ±0.03	0.272 #	0.01 ±0.03
9,10-EpOME	4.02 ±1.61	5.90 ±8.91	0.814 #	-1.88 ±8.52	4.25 ±2.09	4.28 ±2.38	0.638 #	-0.02 ±2.16
12,13-EpOME	4.46 ±1.80	6.87 ±10.61	0.814 #	-2.41 ±10.19	4.42 ±1.84	4.68 ±2.43	0.68	-0.26 ±2.13
9,10-DiHOME	0.912 ±0.49	1.16 ±0.88	0.388 #	-0.24 ±0.69	0.83 ±0.69	1.03 ±0.91	0.023 #	-0.21 ±0.27
12,13-DiHOME	1.46 ±0.77	1.90 ±1.33	0.308 #	-0.44 ±1.25	1.55 ±1.30	1.92 ±1.68	0.136 #	-0.37 ±0.51
7,8-EDP	0.32 ±0.14	0.24 ±0.14	0.158 #	0.08 ±0.17	0.39 ±0.24	0.29 ±0.15	0.116	0.09 ±0.19
10,11-EDP	0.14 ±0.06	0.14 ±0.09	0.638 #	0.00 ±0.09	0.18 ±0.11	0.15 ±0.07	0.388 #	0.03 ±0.09
13,14-EDP	0.13 ±0.07	0.13 ±0.12	0.937 #	0.00 ±0.10	0.13 ±0.09	0.12 ±0.08	0.53 #	0.01 ±0.08
16,17-EDP	0.24 ±0.09	0.21 ±0.11	0.367 #	0.03 ±0.10	0.27 ±0.16	0.22 ±0.12	0.182 #	0.05 ±0.13
19,20-EDP	0.20 ±0.08	0.18 ±0.10	0.48 #	0.02 ±0.11	0.19 ±0.11	0.21 ±0.08	0.568	-0.02 ±0.10
7,8-DiHDPA	0.03 ±0.01	0.03 ±0.01	0.225	0.00 ±0.01	0.05 ±0.01	0.03 ±0.01	0.565	0.00 ±0.01
10,11-DiHDPA	0.03 ±0.02	0.03 ±0.02	0.05 #	0	0.03 ±0.02	0.02 ±0.02	0.308 #	0.00 ±0.01
13,14-DiHDPA	0.04 ±0.01	0.04 ±0.01	0.347 #	0.00 ±0.01	0.04 ±0.01	0.04 ±0.01	0.477 #	0.00 ±0.01
16,17-DiHDPA	0.05 ±0.01	0.05 ±0.01	0.199	0.00 ±0.01	0.05 ±0.01	0.05 ±0.01	0.787	0.00 ±0.01
19,20-DiHDPA	0.31 ±0.16	0.29 ±0.17	0.638 #	0.02 ±0.17	0.47 ±0.37	0.31 ±0.18	0.136 #	0.16 ±0.36
5,6-EEQ	ns	ns	ns	ns	ns	ns	ns	ns
8,9-EEQ	0.13 ±0.07	0.09 ±0.05	0.121	0.03 ±0.07	0.120 ±0.14	0.17 ±0.08	0.583 #	0.03 ±0.14
11,12-EEQ	0.10 ±0.09	0.11 ±0.08	0.814 #	0.00 ±0.11	0.17 ±0.13	0.11 ±0.07	0.388 #	0.05 ±0.13
14,15-EEQ	0.10 ±0.07	0.09 ±0.06	0.814 #	0.01 ±0.08	0.16 ±0.12	0.13 ±0.08	0.814 #	0.03 ±0.14
17,18-EEQ	0.13 ±0.10	0.13 ±0.10	0.875 #	0.00 ±0.11	0.21 ±0.17	0.12 ±0.05	0.099 #	0.09 ±0.16
5,6-DiHETE	0.07 ±0.03	0.06 ±0.03	0.641	0.01 ±0.05	0.08 ±0.04	0.05 ±0.03	0.062	0.03 ±0.05
8,9-DiHETE	0.01 ±0.01	0.01 ±0.01	0.109 #	0	0.01 ±0.01	0.01 ±0.01	1 #	0.00 ±0.01
11,12-DiHETE	0.02 ±0.01	0.02 ±0.01	0.327 #	0.00 ±0.01	0.02 ±0.01	0.01 ±0.00	0.023	0.01 ±0.01
14,15-DiHETE	0.01 ±0.01	0.01 ±0.01	0.875 #	0	0.02 ±0.00	0.01 ±0.00	0.198	0.00 ±0.01
17,18-DiHETE	0.07 ±0.02	0.07 ±0.03	0.986	0.00 ±0.03	0.08 ±0.03	0.07 ±0.03	0.695 #	0.00 ±0.03

Notes: A, arterial blood; V, venous blood. A-V difference; arteriovenous difference. Mean±SD.

Table 3

Effects of hemodialysis on epoxides and their respective diol ratios in the CKD patients before (pre-HD) and at cessation (post-HD) of hemodialysis (n=12 each).

Amount ng/g	pre-HD Arterial	pre-HD Venous	p value, t test (# paired Wilcoxon test)	pre-HD Δ_{A-V}	post-HD Arterial	post-HD Venous	p value, t test (# paired Wilcoxon test)	pre-HD Δ_{A-V}
Panel A: Total metabolite levels.								
5,6-EET + 5,6-DHET	64.79 ±67.79	72.30 ±68.41	0.308 #	-7.51 ±21.72	94.04 ±99.69	58.76 ±63.49	0.308 #	35.28 ±83.82
8,9-EET + 8,9-DHET	65.52 ±15.88	69.56 ±14.81	0.509	-4.04 ±20.53	79.98 ±22.55	66.40 ±13.53	0.055	13.58 ±21.94
11,12-EET + 11,12-DHET	71.55 ±14.37	76.85 ±20.73	0.513	-5.30 ±27.18	85.94 ±25.69	71.43 ±15.93	0.099 #	14.51 ±29.01
14,15-EET + 14,15-DHET	94.36 ±25.30	105.86 ±33.03	0.306	-11.50 ±37.09	111.66 ±40.97	97.05 ±24.40	0.182 #	14.62 ±43.00
12,13-EpOME + 12,13-DiHOME	43.18 ±13.43	46.45 ±9.57	0.399	-3.27 ±12.92	59.67 ±23.23	47.66 ±15.27	0.084 #	12.01 ±26.84
9,10-EpOME + 9,10-DiHOME	39.16 ±16.90	42.30 ±13.10	0.374	-3.14 ±11.74	57.19 ±30.62	42.38 ±19.35	0.099 #	14.81 ±32.19
5,6-EEQ + 5,6-DiHETE	2.62 ±0.99	1.71 ±0.48	0.011 #	0.90 ±1.03	2.22 ±0.73	2.10 ±0.48	0.875 #	0.12 ±0.83
8,9-EEQ + 8,9-DiHETE	3.31 ±2.64	2.87 ±1.25	0.814 #	0.45 ±2.56	4.43 ±2.67	2.95 ±1.43	0.028 #	1.47 ±2.19
11,12-EEQ + 11,12-DiHETE	7.43 ±4.77	7.24 ±3.22	0.903	0.20 ±5.52	10.19 ±3.67	8.29 ±3.82	0.256	1.90 ±5.49
14,15-EEQ + 14,15-DiHETE	2.96 ±1.75	2.87 ±1.49	0.754 #	0.10 ±2.07	3.94 ±1.76	2.66 ±0.99	0.03	1.29 ±1.79
17,18-EEQ + 17,18-DiHETE	5.19 ±4.14	4.48 ±2.19	0.937 #	0.70 ±3.15	7.86 ±6.18	5.12 ±3.80	0.136 #	2.74 ±5.63
7,8-EDP + 7,8-DiHDPA	40.43 ±20.07	41.36 ±19.51	0.884	-0.92 ±21.37	45.61 ±16.82	40.35 ±13.32	0.243	5.26 ±14.78
10,11-EDP + 10,11-DiHDPA	19.71 ±8.67	20.96 ±7.45	0.622	-1.25 ±8.53	25.82 ±9.47	19.03 ±5.58	0.029	6.79 ±9.37
13,14-EDP + 13,14-DiHDPA	18.73 ±10.27	20.53 ±10.58	0.594	-1.80 ±11.36	19.18 ±8.02	15.32 ±4.45	0.151	3.86 ±8.67
16,17-EDP + 16,17-DiHDPA	33.20 ±16.60	37.17 ±15.81	0.475	-3.97 ±18.59	27.83 ±14.51	21.75 ±9.18	0.182 #	6.09 ±14.80
19,20-EDP + 19,20-DiHDPA	24.20 ±10.57	26.26 ±10.68	0.48 #	-2.06 ±12.19	33.29 ±11.81	23.43 ±6.57	0.015 #	9.86 ±13.00
Ratio (9,10-DiHOME+12,13-DiHOME)/ (9,10-EpOME+12,13-EpOME)	0.08 ±0.04	0.06 ±0.03	0.583 #	0.01 ±0.04	0.06 ±0.02	0.08 ±0.03	0.053	-0.02±0.03
Ratio(5,6-DHET+8,9-DHET+11,12- DHET+14,15-DHET)/(5,6-EET+8,9-EET +11,12 EET +14,15-EET)	0.04 ±0.02	0.04 ±0.01	0.53 #	0.00 ±0.02	0.03 ±0.01	0.03 ±0.01	0.51	0.00 ±0.01
Ratio(5,6-DiHETE+8,9-DiHETE+11,12- DiHETE+14,15-DiHETE+17,18-DiHETE)/ (5,6-EEQ+ 8,9-EEQ+11,12-EEQ+14,15- EEQ+17,18-EEQ)	0.57 ±0.19	0.48 ±0.20	0.165	0.09 ±0.21	0.45 ±0.19	0.67 ±0.47	0.117 #	-0.22 ±0.46
Ratio(7,8-DiHDPA+10,11-DiHDPA +13,14- DiHDPA+16,17-DiHDPA+19,20-DiHDPA)/ (7,8-EDP+10,11-EDP+13,14-EDP+16,17- EDP+19,20-EDP)	0.04 ±0.02	0.03 ±0.01	0.583 #	0.00 ±0.02	0.03 ±0.01	0.04 ±0.02	0.199	-0.01 ±0.01
9,10-DiHOME/9,10-EpOME	0.05 ±0.03	0.05 ±0.02	0.615	0.00 ±0.02	0.05 ±0.02	0.05 ±0.02	0.186	-0.01 ±0.02
12,13-DiHOME/12,13-EpOME	0.10 ±0.05	0.08 ±0.03	0.275	0.02 ±0.05	0.08 ±0.03	0.102 ±0.05	0.05 #	-0.02 ±0.04
5,6-DHET/5,6-EET	0.11 ±0.10	0.09 ±0.07	0.48 #	0.02±0.07	0.13 ±0.11	0.11 ±0.10	0.308 #	0.02 ±0.12
8,9-DHET/8,9-EET	0.06 ±0.04	0.06 ±0.03	0.638 #	0.01 ±0.02	0.05 ±0.02	0.05 ±0.03	0.875 #	-0.01 ±0.03
11,12-DHET/11,12-EET	0.031 ±0.01	0.02 ±0.01	0.638 #	0.00 ±0.01	0.02 ±0.01	0.02 ±0.01	0.995	0.00 ±0.01
14,15-DHET/14,15-EET	0.03 ±0.01	0.02 ±0.01	0.463	0.00 ±0.01	0.02 ±0.01	0.02 ±0.01	0.937	0.00 ±0.01
5,6-DiHETE/5,6-EEQ	1940.29 ±1425.66	1107.48 ±699.94	0.003 #	832.81 ±848.10	1242.35 ±1220.11	1551.99 ±1013.06	0.33	-309.64 ±1052.11
8,9-DiHETE/8,9-EEQ	0.08 ±0.03	0.07 ±0.02	0.384	0.01 ±0.03	0.06 ±0.02	0.08 ±0.03	0.042	-0.03 ±0.04
11,12-DiHETE/11,12-EEQ	1.15 ±0.97	1.17 ±0.98	0.388 #	-0.02 ±0.74	1.14 ±0.69	1.44 ±1.26	0.638 #	-0.30 ±1.36
14,15-DiHETE/14,15-EEQ	0.05 ±0.02	0.05 ±0.02	0.859	0.00 ±0.03	0.05 ±0.02	0.05 ±0.02	0.772	0.00 ±0.03
17,18-DiHETE/17,18-EEQ	0.14 ±0.08	0.12 ±0.06	0.324	0.02 ±0.06	0.09 ±0.06	0.14 ±0.08	0.032	-0.06 ±0.08
7,8-DiHDPA/7,8-EDP	0.04 ±0.02	0.04 ±0.01	0.638 #	0.00 ±0.01	0.03 ±0.01	0.03 ±0.02	0.308 #	0.00 ±0.01
10,11-DiHDPA/10,11-EDP	0.0477 ±0.0250	0.0421 ±0.0202	0.433 #	0.0056 ±0.0206	0.0342 ±0.0149	0.0427 ±0.0179	0.187	-0.0085 ±0.0208

(continued on next page)

Table 3 (continued)

Amount ng/g	pre-HD Arterial	pre-HD Venous	p value, t test (# paired Wilcoxon test)	pre-HD Δ_{A-V}	post-HD Arterial	post-HD Venous	p value, t test (# paired Wilcoxon test)	pre-HD Δ_{A-V}
13,14-DiHDDPA/13,14-EDP	0.06 ±0.03	0.05 ±0.03	0.347 #	0.01 ±0.03	0.06 ±0.03	0.07 ±0.05	0.388 #	-0.01 ±0.03
16,17-DiHDDPA/16,17-EDP	0.02 ±0.02	0.02 ±0.01	0.48 #	0.00 ±0.02	0.03 ±0.02	0.03 ±0.02	0.853	0.00 ±0.02
19,20-DiHDDPA/19,20-EDP	0.06±0.02	0.05 ±0.02	0.209 #	0.01 ±0.02	0.04 ±0.01	0.05 ±0.01	0.373	-0.01 ±0.02
Panel B: Free metabolite levels.								
11,12-EET + 11,12-DHET	0.88 ±0.30	0.66 ±0.25	0.099 #	0.22 ±0.41	1.26 ±0.61	1.00 ±0.39	0.28	0.26 ±0.80
14,15-EET + 14,15-DHET	0.95 ±0.32	0.76 ±0.32	0.136 #	0.19 ±0.44	1.50 ±0.63	1.10 ±0.33	0.091	0.40 ±0.74
5,6-EET + 5,6-DHET	0.70 ±0.32	0	0.388 #	0.11 ±0.44	1.04 ±0.49	0	0.272 #	0.21 ±0.58
8,9-EET + 8,9-DHET	1.46 ±0.76	0.12 ±0.08	0.83	-0.06 ±0.87	1.56 ±0.88	0.13 ±0.07	0.817	0.07 ±0.95
9,10-EpOME + 9,10-DiHOME	4.94 ±1.86	0.59 ±0.33	0.875 #	-2.11 ±9.18	5.08 ±2.40	0.83 ±0.32	0.739	-0.230 ±2.34
12,13-EpOME + 12,13-DiHOME	5.92 ±2.41	1.51 ±1.00	1 #	-2.85 ±11.33	5.97±2.50	1.49±0.68	0.754 #	-0.63 ±2.46
5,6-EEQ + 5,6-DiHETE	0	0.11 ±0.06	1 #	0	0	0.15 ±0.08	1 #	0
8,9-EEQ + 8,9-DiHETE	0.14 ±0.08	0.20 ±0.12	0.158 #	0.04 ±0.07	0.21 ±0.14	0.20 ±0.08	0.583 #	0.04 ±0.14
11,12-EEQ + 11,12-DiHETE	0.12 ±0.09	0.27 ±0.14	0.754 #	0.00 ±0.11	0.19 ±0.14	0.33 ±0.15	0.272 #	0.06 ±0.14
14,15-EEQ + 14,15-DiHETE	0.12 ±0.07	0.10 ±0.05	0.638 #	0.01 ±0.08	0.18 ±0.12	0.17 ±0.07	0.814 #	0.03 ±0.14
17,18-EEQ + 17,18-DiHETE	0.20 ±0.12	0.12 ±0.10	0.814 #	0.00 ±0.12	0.29 ±0.18	0.07 ±0.04	0.158 #	0.09 ±0.17
7,8-EDP + 7,8-DiHDDPA	0.35 ±0.14	0.17 ±0.12	0.117 #	0.08 ±0.17	0.42 ±0.25	0.16 ±0.09	0.132	0.09 ±0.19
10,11-EDP + 10,11-DiHDDPA	0.17 ±0.06	0.27 ±0.11	0.695 #	0.00 ±0.09	0.21 ±0.15	0.27 ±0.12	0.298	0.03 ±0.09
13,14-EDP + 13,14-DiHDDPA	0.17 ±0.07	0.47 ±0.22	0.937 #	0.00 ±0.10	0.17 ±0.10	0.52 ±0.22	0.628	0.01 ±0.08
16,17-EDP + 16,17-DiHDDPA	0.29 ±0.09	0.17 ±0.09	0.53 #	0.03 ±0.10	0.32 ±0.16	0.18 ±0.07	0.182 #	0.05 ±0.13
19,20-EDP + 19,20-DiHDDPA	0.51 ±0.19	0.34 ±0.14	0.584	0.04 ±0.23	0.66 ±0.39	0.34 ±0.17	0.176	0.15 ±0.35
Ratio(5,6-DHET+8,9-DHET+11,12-DHET+14,15-DHET)/(5,6-EET+8,9-EET+11,12 EET +14,15-EET)	0.11 ±0.11	0.14 ±0.09	0.308 #	-0.01 ±0.07	0.07 ±0.05	0.08 ±0.04	0.695 #	0.00 ±0.05
Ratio(5,6-DiHETE+8,9-DiHETE+11,12-DiHETE+14,15-DiHETE+17,18-DiHETE)/(5,6-EEQ+ 8,9-EEQ+11,12-EEQ+14,15-EEQ+17,18-EEQ)	0.49±0.21	0.17±0.10	0.556	-0.06 ±0.33	0.34 ±0.13	0.09 ±0.04	0.638	0.02 ±0.14
Ratio (9,10-DiHOME+12,13-DiHOME)/(9,10-EpOME+12,13-EpOME)	0.29 ±0.12	0.55 ±0.33	0.305	-0.05 ±0.17	0.29 ±0.18	0.32 ±0.08	0.183	-0.05 ±0.11
Ratio(7,8-DiHDDPA+10,11-DiHDDPA +13,14-DiHDDPA+16,17-DiHDDPA+19,20-DiHDDPA)/(7,8-EDP+10,11-EDP+13,14-EDP+16,17-EDP+19,20-EDP)	0.50 ±0.19	0.61 ±0.36	0.308 #	-0.11 ±0.34	0.70 ±0.60	0.56 ±0.39	0.583 #	0.14 ±0.71
9,10-DiHOME/9,10-EpOME	0.24 ±0.13	0.27 ±0.15	0.439	-0.03 ±0.13	0.21 ±0.13	0.24 ±0.12	0.164	-0.04 ±0.08
12,13-DiHOME/12,13-EpOME	0.34 ±0.1301	0.4102 ±0.1598	0.288	-0.0710 ±0.2201	0.3751 ±0.2404	0.4241 ±0.2253	0.308 #	-0.0490 ±0.1422
5,6-DHET/5,6-EET	0.07 ±0.05	0.07 ±0.04	0.48 #	0.00 ±0.05	0.04 ±0.03	0.04 ±0.03	0.583 #	0.00±0.02
8,9-DHET/8,9-EET	0.16 ±0.24	0.20 ±0.33	0.388 #	-0.04 ±0.32	0.10 ±0.13	0.09 ±0.10	1 #	0.01 ±0.06
11,12-DHET/11,12-EET	0.13 ±0.15	0.25 ±0.24	0.48 #	-0.01 ±0.11	0.08 ±0.07	0.12 ±0.08	0.388 #	0.00 ±0.07
14,15-DHET/14,15-EET	0.15 ±0.16	7.05 ±9.62	0.182 #	-0.02 ±0.13	0.08 ±0.07	5.31 ±3.03	0.433 #	-0.014 ±0.07
5,6-DiHETE/5,6-EEQ	0	0	1 #	0	0	0	1 #	0
8,9-DiHETE/8,9-EEQ	0.081 ±0.16	0.07 ±0.14	1 #	0.00 ±0.09	0.04 ±0.09	0.04 ±0.08	1 #	0.00±0.05
11,12-DiHETE/11,12-EEQ	0.29 ±0.19	0.26 ±0.28	0.638 #	0.03 ±0.28	0.21 ±0.26	0.13 ±0.05	0.239 #	0.08 ±0.25
14,15-DiHETE/14,15-EEQ	0.17 ±0.09	0.74 ±0.38	0.695 #	-0.07 ±0.26	0.12 ±0.06	0.70 ±0.43	0.937 #	0.00 ±0.11
17,18-DiHETE/17,18-EEQ	0.92 ±0.88	8.77 ±11.80	0.875 #	0.18 ±1.03	0.49 ±0.30	6.60 ±3.54	0.308 #	-0.22 ±0.55
7,8-DiHDDPA/7,8-EDP	0.14 ±0.13	0.15 ±0.09	0.347 #		0.11 ±0.08	0.14 ±0.07	0.182 #	

(continued on next page)

Table 3 (continued)

Amount ng/g	pre-HD Arterial	pre-HD Venous	p value, t test (# paired Wilcoxon test)	pre-HD Δ_{A-V}	post-HD Arterial	post-HD Venous	p value, t test (# paired Wilcoxon test)	pre-HD Δ_{A-V}
10,11-DiHDPA/10,11-EDP	0.23 \pm 0.25	0.24 \pm 0.17	0.158 #	-0.01 \pm 0.13 -0.01 \pm 0.16	0.19 \pm 0.17	0.18 \pm 0.10	0.875 #	-0.03 \pm 0.08 0.01 \pm 0.15
13,14-DiHDPA/13,14-EDP	0.53 \pm 0.44	0.61 \pm 0.45	0.638 #	-0.08 \pm 0.62	0.46 \pm 0.43	0.44 \pm 0.22	0.308 #	0.02 \pm 0.44
16,17-DiHDPA/16,17-EDP	0.26 \pm 0.15	0.30 \pm 0.13	0.308 #	-0.05 \pm 0.15	0.23 \pm 0.12	0.29 \pm 0.18	0.48 #	-0.06 \pm 0.21
19,20-DiHDPA/19,20-EDP	1.81 \pm 1.15	1.97 \pm 1.29	0.53 #	-0.16 \pm 0.95	3.53 \pm 3.36	1.73 \pm 1.35	0.084 #	1.80 \pm 3.37

Notes: Ratios were estimated using total concentrations of epoxides and diols in RBCs. A, arterial blood; V, venous blood. A-V difference; arteriovenous difference. Mean \pm SD.

This error did not alter the data or conclusions of the article in any way.

However, we also noticed that the layout of the tables has not been appropriately formatted. The tables that were originally submitted are now presented below.

Tables 1, 2 and 3

The authors all agree to the publication of this corrigendum, and are grateful to the Editor of Prostaglandins, Leukotrienes and Essential Fatty Acids for allowing them the opportunity to publish this. The authors would like to apologise for any inconvenience caused.